This novel study was specifically designed for platinum-resistant recurrent ovarian cancers with PFI\<6 months and aimed to compare prognosis of patients who received cytoreductive surgery followed by chemotherapy versus chemotherapy alone.
Patients with diagnosis of epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma within 3 lines recurrence;
Recurrence occurred within 6 months since platinum-based chemotherapy;
R0 ideal debulking in initial surgery; PET-CT indicate the recurrence lesion is almost in abdominal cavity, which is isolated and not exceed 5 sites, and the ascites is less than 500ml;
ECOG/WHO Performance score of 0 to 1;
Platinum-refractory/uncontrolled epithelial ovarian cancer;
Mucous carcinoma or low-grade serous carcinoma;
Suffering from other malignant tumors that have not achieved complete remission in the past 2 years;
Patients have received abdominal or pelvic radiotherapy;